Abstract
Background: The present study deals with the formulation and optimization of piroxicam fast dissolving tablets and analyzes the impact of an independent variable while selecting the optimized formulation utilizing Quality by Design (QbD) and Box-Behnken Design (BBD).
Method: Seventeen formulations were prepared by direct compression technique by altering the proportion of cross carmellose sodium, spray dried lactose and hydro propyl methyl cellulose (HPMC K4M). The BBD statistical technique was used to optimize formulations and correlate the relationship among all the variables. Also, the powder mixture characteristics and tablet physiochemical properties such as hardness, friability, drug content, Disintegration Time (DT) and dissolution test were determined using 900 ml of 0.1N HCl (pH-1.2) at 37 ± 0.5°C.
Result: Significant quadratic model and second order polynomial equations were established using BBD. To find out the relationship between variables and responses, 3D response surface and 2D contour plot was plotted. A perturbation graph was also plotted to identify the deviation of the variables from the mean point. An optimized formula was prepared based on the predicted response and the resulting responses were observed to be close with the predicted value.
Conclusion: The optimized formulation with the desired parameter and formulation with variables and responses can be obtained by BBD and could be used in the large experiment with the involvement of a large number of variables and responses.
Keywords: Fast dissolving tablet, piroxicam, Box-Behnken design, direct compression technique, response surface, contour plot.
Graphical Abstract
[http://dx.doi.org/10.1016/j.xphs.2017.05.004 ] [PMID: 28499879]
[http://dx.doi.org/10.1016/j.ejps.2017.03.042] [PMID: 28366649]
[http://dx.doi.org/10.1016/j.jsps.2017.05.003] [PMID: 29158720]
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.033] [PMID: 28522425]
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.004] [PMID: 29031980]
[http://dx.doi.org/10.1080/03639045.2017.1414233] [PMID: 29252038]
[http://dx.doi.org/10.1016/j.ejpb.2010.12.012] [PMID: 21168490]
[http://dx.doi.org/10.1016/j.ijpharm.2011.12.024] [PMID: 22209997]
[http://dx.doi.org/10.2478/v10007-008-0006-3] [PMID: 18515232]
[http://dx.doi.org/10.1016/j.jddst.2018.07.015]
[http://dx.doi.org/10.1016/j.arabjc.2013.03.005]
[http://dx.doi.org/10.1016/j.molliq.2017.03.042]
[http://dx.doi.org/10.1016/0378-5173(95)04216-4]
[http://dx.doi.org/10.4103/2230-973X.143116] [PMID: 25426438]
[http://dx.doi.org/10.12980/APJTB.4.2014B672] [PMID: 25183106]
[http://dx.doi.org/10.1016/j.ejpb.2016.09.011] [PMID: 27658987]
[http://dx.doi.org/10.1007/s12272-011-1115-y] [PMID: 22139694]
[http://dx.doi.org/10.1016/j.jsps.2017.10.013] [PMID: 29379333]
[http://dx.doi.org/10.1016/S0378-5173(96)04784-9]
[http://dx.doi.org/10.1007/s11434-012-5094-2]
[PMID: 26100758]
[http://dx.doi.org/10.2174/2211738503666150501003906]